Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor
    Journal Article

    Helman, E.; Nguyen, M.; Karlovich, C. A.; Despain, D.; Choquette, A. K.; Spira, A. I.; Yu, H. A.; Camidge, D. R.; Harding, T. C.; Lanman, R. B.; more...
    Clinical Lung Cancer (2018)

    Fulltext@MSK | Save
  • ERBBal remedies: Combination therapy for EGFR-mutant lung cancers
    Journal Article

    Fan, P. D.; Yu, H. A.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Sequencing therapy for genetically defined subgroups of non-small cell lung cancer
    Journal Article

    Yu, H. A.; Planchard, D.; Lovly, C. M.
    American Society of Clinical Oncology Educational Book (2018)

    Fulltext@MSK | Save
  • YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Journal Article

    Fan, P. D.; Narzisi, G.; Jayaprakash, A. D.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Yu, H. A.; Jordan, E. J.; Paik, P. K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
    Journal Article

    Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer
    Journal Article

    Arbour, K. C.; Jordan, E.; Kim, H. R.; Dienstag, J.; Yu, H. A.; Sanchez-Vega, F.; Lito, P.; Berger, M.; Solit, D. B.; Hellmann, M.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC
    Meeting Abstract

    Arbour, K. C.; Sequist, L. V.; Piotrowska, Z.; Kris, M. G.; Paik, P. K.; Ni, A.; Plodkowski, A.; Riely, G.; Yu, H. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical activity of osimertinib in EGFR mutation positive non-small cell lung cancer (NSCLC) patients (pts) previously treated with rociletinib
    Meeting Abstract

    Gadgeel, S.; Chen, W.; Piotrowska, Z.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Varga, A.; Yu, H.; Papadimitrakopoulou, V.; Nea, J.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save